polypeptide protects dopaminergic neurons from apoptosis induced by rotenone and 6-hydroxydopamine.

Su Peng, Li Xu, Jin-Yu Ma, Xiao-Song Gu, Cheng Sun
Author Information
  1. Su Peng: Key Laboratory for Neuroregeneration of Jiangsu Province and Ministry of Education, Co-Innovatioin Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China.
  2. Li Xu: Key Laboratory for Neuroregeneration of Jiangsu Province and Ministry of Education, Co-Innovatioin Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China.
  3. Jin-Yu Ma: Key Laboratory for Neuroregeneration of Jiangsu Province and Ministry of Education, Co-Innovatioin Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China.
  4. Xiao-Song Gu: Key Laboratory for Neuroregeneration of Jiangsu Province and Ministry of Education, Co-Innovatioin Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China.
  5. Cheng Sun: Key Laboratory for Neuroregeneration of Jiangsu Province and Ministry of Education, Co-Innovatioin Center of Neuroregeneration, Nantong University, Nantong, Jiangsu Province, China.

Abstract

It has been well documented that Achyranthes bidentata polypeptides (ABPPs) are potent neuroprotective agents in several types of neurons. However, whether ABPPs protect dopaminergic neurons from apoptosis induced by neurotoxins is still unknown. This study was designed to observe the effect of ABPPk, a purified fraction of ABPPs, on apoptosis of dopaminergic neurons. SH-5YHY cells and primary dopaminergic neurons were pre-treated with ABPPk (25, 50, or 100 ng/mL) for 12 hours. Cells were then exposed to 6-hydroxydopamine (50 or 150 μM) or rotenone (50 or 200 μM) for 36 hours to induce cell apoptosis. Our results demonstrate that ABPPk markedly increased viability in SH-SY5Y cells and primary dopaminergic neurons, decreased lactate dehydrogenase activity and number of apoptotic dopaminergic neurons, elevated mitochondrial membrane potential, and increased Bcl-2/Bax ratio. These findings suggest that ABPPk protects dopaminergic neurons from apoptosis, and that ABPPk treatment might be an effective intervention for treating dopaminergic neuronal loss associated with disorders such as Parkinson's disease.

Keywords

References

  1. J Neurosci Res. 2010 Feb 15;88(3):669-76 [PMID: 19774671]
  2. Brain Res Bull. 2010 Jan 15;81(1):25-32 [PMID: 19646511]
  3. Cell Death Dis. 2014 May 29;5:e1266 [PMID: 24874738]
  4. Neural Regen Res. 2014 Dec 15;9(24):2142-50 [PMID: 25657735]
  5. Cell Biochem Biophys. 2014 Sep;70(1):467-73 [PMID: 24728946]
  6. Int Immunopharmacol. 2011 Aug;11(8):1103-8 [PMID: 21439398]
  7. PLoS One. 2014 Oct 15;9(10):e109923 [PMID: 25334016]
  8. Neurochem Res. 2011 Nov;36(11):2186-94 [PMID: 21735136]
  9. Sci Rep. 2016 Aug 05;6:31049 [PMID: 27491681]
  10. PLoS One. 2013;8(2):e57055 [PMID: 23468912]
  11. Parkinsons Dis. 2011;2011:159160 [PMID: 21687805]
  12. J Neurochem. 1996 May;66(5):2004-10 [PMID: 8780029]
  13. Int J Mol Sci. 2013 Sep 30;14(10):19792-804 [PMID: 24084726]
  14. Brain Res Bull. 2008 Nov 25;77(5):274-81 [PMID: 18765272]
  15. Cytotechnology. 2014 Dec;66(6):925-35 [PMID: 24113920]
  16. Mol Cell. 2009 Mar 13;33(5):627-38 [PMID: 19285945]
  17. J Physiol Biochem. 2014 Sep;70(3):735-47 [PMID: 24986222]
  18. Nat Prod Rep. 2015 Dec 19;32(12):1617-21 [PMID: 26561737]
  19. J Cell Biol. 1992 Nov;119(3):493-501 [PMID: 1400587]
  20. Sci Rep. 2017 Jun 20;7(1):3888 [PMID: 28634392]
  21. Neurochem Res. 2013 Mar;38(3):538-46 [PMID: 23242788]
  22. Evid Based Complement Alternat Med. 2014;2014:158018 [PMID: 24963319]
  23. J Neurosci. 2003 Nov 26;23(34):10756-64 [PMID: 14645467]
  24. J Neurosci. 2015 Jul 29;35(30):10731-49 [PMID: 26224857]
  25. J Biol Chem. 2005 Dec 23;280(51):42026-35 [PMID: 16243845]
  26. Cell Rep. 2014 Dec 24;9(6):2250-62 [PMID: 25497092]
  27. Eur J Pharmacol. 1995 Mar 16;292(3-4):329-32 [PMID: 7796873]

Word Cloud

Created with Highcharts 10.0.0neuronsdopaminergicapoptosisABPPkABPPs50cellAchyranthesbidentatapolypeptidesinducedcellsprimaryhours6-hydroxydopamineμMrotenoneincreasedviabilitymitochondrialBcl-2/BaxprotectsregenerationwelldocumentedpotentneuroprotectiveagentsseveraltypesHoweverwhetherprotectneurotoxinsstillunknownstudydesignedobserveeffectpurifiedfractionSH-5YHYpre-treated25100ng/mL12Cellsexposed15020036induceresultsdemonstratemarkedlySH-SY5YdecreasedlactatedehydrogenaseactivitynumberapoptoticelevatedmembranepotentialratiofindingssuggesttreatmentmighteffectiveinterventiontreatingneuronallossassociateddisordersParkinson'sdiseasepolypeptidedysfunctionnerveneuralneuroprotectionneurotoxin

Similar Articles

Cited By